Comparative Pharmacology
Head-to-head clinical analysis: SULFAPYRIDINE versus SULSTER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAPYRIDINE versus SULSTER.
SULFAPYRIDINE vs SULSTER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
Sulster is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thus bacterial DNA replication.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
2.5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
Terminal half-life 3.5-4.5 hours in normal renal function; prolonged to 10-15 hours with creatinine clearance <30 mL/min.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Primarily renal (60-70% unchanged), with 20-30% as glucuronide conjugate; biliary/fecal <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic